On December 3, 2015, Astellas Pharma US, Inc. (the U.S. affiliate of Astellas Pharma Inc.), a R&D-driven global pharmaceutical company, invited the Foundation for Peripheral Neuropathy to present to a global team working on development of ASP3662 for patients with neuropathic pain (NP). This was an internal meeting, which included Ulf Tollemar, Executive Director, Development […]
FPN Connects Peripheral Neuropathy Researchers at Astellas Pharma to the Patients They Are Hoping to Serve
